Intervention Review

You have free access to this content

Antibiotics versus placebo for acute bacterial conjunctivitis

  1. Aziz Sheikh1,*,
  2. Brian Hurwitz2,
  3. Constant Paul van Schayck3,
  4. Susannah McLean4,
  5. Ulugbek Nurmatov5

Editorial Group: Cochrane Eyes and Vision Group

Published Online: 12 SEP 2012

Assessed as up-to-date: 18 JUL 2012

DOI: 10.1002/14651858.CD001211.pub3

How to Cite

Sheikh A, Hurwitz B, van Schayck CP, McLean S, Nurmatov U. Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database of Systematic Reviews 2012, Issue 9. Art. No.: CD001211. DOI: 10.1002/14651858.CD001211.pub3.

Author Information

  1. 1

    The University of Edinburgh, Centre for Population Health Sciences, Edinburgh, UK

  2. 2

    King's College London, London, UK

  3. 3

    Maastricht University, Department of General Practice, Maastricht, Netherlands

  4. 4

    The University of Edinburgh, Allergy & Respiratory Research Group, Centre for Population Health Sciences, Edinburgh, Scotland, UK

  5. 5

    Centre for Population Health Sciences, The University of Edinburgh, Allergy & Respiratory Research Group, Edinburgh, UK

*Aziz Sheikh, Centre for Population Health Sciences, The University of Edinburgh, Medical School, Doorway 3, Teviot Place, Edinburgh, EH8 9AG, UK. Aziz.Sheikh@ed.ac.uk.

Publication History

  1. Publication Status: New search for studies and content updated (conclusions changed)
  2. Published Online: 12 SEP 2012

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
  5. References to other published versions of this review
Abelson 2008 {published data only}
  • Abelson MB, Heller W, Shapiro AM, Si E, Hsu P, Bowman LM. Clinical cure of bacterial conjunctivitis with azithromycin 1%: vehicle-controlled, double-masked clinical trial. American Journal of Ophthalmology 2008;145:959-65.
Gigliotti 1984 {published data only}
Gross 2003 {published data only}
  • Gross RD, Lichtenstein SJ, Schlech BA, Gower LA, Potts SL. Early clinical and microbiological responses in the treatment of bacterial conjunctivitis with moxifloxacin ophthalmic solution 0.5% (Vigamox TM) using b.i.d dosing. Today's Therapeutic Trends 2003;21(2):227-37.
Karpecki 2009 {published data only}
  • Karpecki P, DePaolis M, Hunter JA, White EM, Rigel L, Brunner LS, et al. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: a multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study. Clinical Therapeutics 2009;31(3):514-26.
Leibowitz 1991 {published data only}
  • Leibowitz HM. Antibacterial effectiveness of ciprofloxacin 0.3% ophthalmic solution in the treatment of bacterial conjunctivitis. American Journal of Ophthalmology 1991;112:29S-33S.
Miller 1992 {published data only}
  • Miller IM, Wittreich J, Vogel R, Cook TJ. The safety and efficacy of topical norfloxacin compared with placebo in the treatment of acute, bacterial conjunctivitis. European Journal of Ophthalmology 1992;2:58-66.
Rietveld 2005 {published data only}
  • Rietveld RP, ter Riet G, Bindels PJ, Bink D, Sloos JH, van Weert HC. The treatment of acute infectious conjunctivitis with fusidic acid: a randomised controlled trial. British Journal of General Practice 2005;55:924-30.
Rose 2005 {published data only}
  • Rose PW, Harnden A, Brueggemann AB, Perera R, Sheikh A, Crook D, et al. Chloramphenicol treatment for acute infective conjunctivitis in children in primary care: a randomised double-blind placebo-controlled trial. Lancet 2005;366:37-43.
Silverstein 2011 {published data only}
  • Silverstein BE, Allaire C, Bateman KM, Gearinger LS, Morris TW, Comstock TL. Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children. Clinical Therapeutics 2011;33(1):13-26.
Tauber 2011 {published data only}
  • Tauber S, Cupp G, Garber R, Bartell J, Vohra F, Stroman D. Microbiological efficacy of a new ophthalmic formulation of moxifloxacin dosed twice-daily for bacterial conjunctivitis. Advances in Therapy 2011;28(7):566-74.
Tepedino 2009 {published data only}
  • Tepedino ME, Heller WH, Usher DW, Brunner LS, Morris TW, Haas W, et al. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Current Medical Research and Opinion 2009;25(5):1159-69.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
  5. References to other published versions of this review
Bremond-Gignac 2010 {published data only}
  • Bremond-Gignac D, Mariani-Kurkdjian P, Beresniak A, El Fekih L, Bhagat Y, Pouliquen P, et al. Efficacy and safety of azithromycin 1.5% eye drops for purulent bacterial conjunctivitis in pediatric patients. Pediatric Infectious Disease Journal 2010;29(3):222-6.
Denis 2008 {published data only}
  • Denis F, Chaumeil C, Goldschmidt P, Delval L, Pouliquen P, Cochereau I, et al. Microbiological efficacy of 3-day treatment with azithromycin 1.5% eye-drops for purulent bacterial conjunctivitis. European Journal of Ophthalmology 2008;18(6):858-68.
Everitt 2006 {published data only}
Granet 2008 {published data only}
  • Granet DB, Dorfman M, Stroman D, Cockrum P. A multicenter comparison of polymyxin B sulfate/trimethoprim ophthalmic solution and moxifloxacin in the speed of clinical efficacy for the treatment of bacterial conjunctivitis. Journal of Pediatric Ophthalmology and Strabismus 2008;45(6):340-9.
Leibowitz 1976 {published data only}
McDonald 2009 {published data only}
  • McDonald MB, Protzko EE, Brunner LS, Morris TW, Haas W, Paterno MR, et al. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis. Ophthalmology 2009;116(9):1615-23.
Mitsui 1986 {published data only}
  • Mitsui Y, Matsuda H, Miyajima T, Tazawa, Kumagai S. Therapeutic effects of ofloxacin eye drops (DE-055) on external infection of the eye: multicentral double blind test. Japanese Review of Clinical Ophthalmology 1986;80:1813-28.
Robert 2010 {published data only}
  • Robert PY, Bourcier T, Meddeb-Ouertani A, Khairallah M, Zaghloul K, Amraoui A, et al. Efficacy assessment of azithromycin 1.5% eye drops versus tobramycin 0.3% on clinical signs of purulent bacterial conjunctivitis. Journal Français D'Ophtalmologie 2010;33(4):241-8.
Szaflik 2009 {published data only}
  • Szaflik J, Szaflik JP, Kaminska A, Levofloxacin Bacterial Conjunctivitis Dosage Study Group. Clinical and microbiological efficacy of levofloxacin administered three times a day for the treatment of bacterial conjunctivitis. European Journal of Ophthalmology 2009;19(1):1-9.
Ta 2007 {published data only}
  • Ta CN, Sinnar S, He L, Myung D, Mino De Kaspar H. Prospective randomized comparison of 1-day versus 3-day application of topical levofloxacin in eliminating conjunctival flora. European Journal of Ophthalmology 2007;17(5):689-95.

References to studies awaiting assessment

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
  5. References to other published versions of this review
NCT00509873 {published data only}
  • NCT00509873. A study of the safety and efficacy of gatifloxacin in patients with bacterial conjunctivitis. http://clinicaltrials.gov/ct2/show/NCT00509873 (accessed 8 January 2012).
NCT00518089 {published data only}
  • NCT00518089. A study of the safety and efficacy of gatifloxacin in patients with bacterial conjunctivitis. http://clinicaltrials.gov/ct2/show/NCT00518089 (accessed 8 January 2012).
NCT01175590 {published data only}
  • NCT01175590. Safety of Besivance™ (Besifloxacin ophthalmic suspension) 0.6% compared to vehicle. http://clinicaltrials.gov/ct2/show/NCT01175590 (accessed 8 January 2012).
Ofloxacin 1990 {published data only}
  • Oxfloxacin Study Group III. A placebo-controlled clinical study of the fluoroquinolone ofloxacin in patients with external infection. Investigative Ophthalmology & Visual Science 1990;31(4):572.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
  5. References to other published versions of this review
Dart 1986
Del Mar 2004
  • Del Mar CB, Glasziou PP, Spinks AB. Antibiotics for sore throat. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858.CD000023.pub3]
Doona 1995
Glanville 2006
  • Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. 2006 64;2:130-6.
Glasziou 2004
  • Glasziou PP, Del Mar CB, Sanders SL, Hayem M. Antibiotics versus placebo for acute otitis media in children. Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: 10.1002/14651858.CD000219.pub2]
Higgins 2011
  • Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Hovding 1991
  • Hovding G, Bratland SZ, Digranes A. Rodt oye - praktisk veiledning i allmenn praksis. Oslo: Lovens Kemiske Fabrik, 1991.
Hovding 2008
Hurwitz 2005
  • Hurwitz B, Sheikh A. Topical antibiotics for acute bacterial conjunctivitis: Cochrane systematic review and meta-analysis update. British Journal of General Practice 2005;55:962-4.
Jefferis 2011
  • Jefferis J, Perera R, Everit H, van Weert H, Rietveld R, Glasziou P, et al. Acute infective conjunctivitis in primary care: who needs antibiotics? An individual patient data-analysis. British Journal of General Practice 2011;61(690):e542-8.
Kodjikian 2010
  • Kodjikian L, Lafuma A, Khoshnood B, Laurendeau C, Berdeaux G. Efficacy of moxifloxacin in treating bacterial conjunctivitis: a meta-analysis. Journal Francais D'Ophtalmologie 2010;33:227-33.
Lancaster 1998
McCormick 1995
  • McCormick A, Fleming D, Charlton J. Morbidity statistics from general practice. Fourth national study 1991-2. London: HMSO, 1995.
McDonnell 1988
McLean 2010
  • McLean S, Sheikh A. Effectiveness, tolerability and safety of azithromycin 1% in DuraSite for acute bacterial conjunctivitis. Patient Preference and Adherence 2010;4:69-76.
Review Manager 2011
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Stern 2011
  • Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Terrin 2005
  • Terrin N, Schmid CH, Lau J. In an empirical evaluation of the funnel plot, researchers could not visually identify publication bias. Journal of Clinical Epidemiology 2005;58(9):894-901.
Wald 1997

References to other published versions of this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
  5. References to other published versions of this review
Sheikh 2000
  • Sheikh A, Hurwitz B, Cave J. Antibiotics for acute bacterial conjunctivitis. Cochrane Database of Systematic Reviews 2000, Issue 2. [DOI: 10.1002/14651858.CD001211]
Sheikh 2001
Sheikh 2006